Introduction {#section5-2050313X17742836}
============

Treatment for schizophrenia requires the administration of antipsychotic drugs not just in the acute phase but also in the maintenance or stable phase, in order to prevent relapse.^[@bibr1-2050313X17742836]^ However, owing to the various adverse effects of antipsychotic drugs, including extrapyramidal symptoms (EPS), cardiovascular diseases, and metabolic abnormalities, due consideration must be given to minimizing their use in the maintenance phase. Antipsychotic drugs are given by tapering their dose, extending the dosing interval, and so on, as part of a treatment strategy to minimize the adverse effects while at the same time maintaining efficacy. We already reported benefit of extending the dosing interval of long-acting antipsychotic injections on two schizophrenia patients including this case.^[@bibr2-2050313X17742836]^ Although the order of the article has been changed, we still report the effects of a long-acting antipsychotic injection that was administered at least 24 months before in one patient with schizophrenia whose clinical symptoms were alleviated by treatment with 6 mg of paliperidone. Here, we report the case of one patient with schizophrenia in whom the clinical symptoms were alleviated after treatment with 6 mg paliperidone. However, the patient developed extrapyramidal symptoms (EPS), for which 3 and 6 mg paliperidone were administered alternately every other day.

Case report {#section6-2050313X17742836}
===========

The report was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients. The anonymity of the patient has been preserved. Patient had been diagnosed with schizophrenia according to the *Diagnostic and Statistical Manual of Mental Disorders* (4th ed., text rev.; DSM-IV-TR) criteria. EPS was assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS),^[@bibr3-2050313X17742836]^ Abnormal Involuntary Movement Scale (AIMS),^[@bibr4-2050313X17742836]^ or Barnes Akathisia Scale (BAS).^[@bibr5-2050313X17742836]^ Patient fulfilled the following criteria for at least 6 months during paliperidone 6 mg treatment, and patient's mental symptoms were stable: (1) Positive and Negative Syndrome Scale (PANSS)^[@bibr6-2050313X17742836]^ total score \<70 and (2) a score below 3 for all the parameters in PANSS, namely, conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content ([Table 1](#table1-2050313X17742836){ref-type="table"}).

###### 

Subject characteristics.

![](10.1177_2050313X17742836-table1)

  ---------------------------------- ----
  Age (years)                        23
  Education (years)                  14
  Duration of illness (years)        5
  Age at onset (years)               18
  Hospitalization history            0
  PANSS total score (baseline)       65
   Conceptual disorganization        2
   Hallucinatory behavior            2
   Suspiciousness                    2
   Unusual thought content           1
  Paliperidone (mg/day) (baseline)   6
  ---------------------------------- ----

PANSS: Positive and Negative Syndrome Scale.

The outpatient was a 23-year-old woman with paranoid schizophrenia (duration of illness, 6 years), observed bradykinesia, dystonia, and dyskinesia under paliperidone 6 mg treatment. Mild EPS was observed during the paliperidone treatment (6 mg). However, because the patient's psychiatric symptoms were stabilized, the patient very much wanted to avoid recurrence. Therefore, 3 and 6 mg daily doses were alternated. Because it avoided the risk of worsening patient's mental symptoms under paliperidone 3 mg treatment, 3 and 6 mg paliperidone were administered alternately every other day. The following characteristics improved, 6 months after 3 and 6 mg paliperidone were administered alternately every other day: PANSS total score (65 to 61), negative score (21 to 19), general score (33 to 31), DIEPSS (8 to 6), and AIMS (10 to 8). On the contrary, there was no change in the PANSS positive score (11 to 11) and BAS (0 to 0).

Discussion {#section7-2050313X17742836}
==========

In this study, alternating the daily doses (3 and 6 mg) of paliperidone resulted in improved clinical scores, including a minimal change in the total PANSS score. In addition, the stability of the psychiatric symptoms was maintained, and the EPS were somewhat ameliorated, which improved the patient's quality of life and living skills and increased the patient's satisfaction. In clinical practice, the dosing interval is generally prescribed on the basis of serum half-life, although its validity has not been investigated thoroughly. Consistent with previous studies,^[@bibr7-2050313X17742836]^ it is suggested that paliperidone dose reduction in stabilized schizophrenic patients improve the negative symptoms, bradykinesia, dystonia, and dyskinesia, without increasing the risk of a relapse. Consistent with this case report, earlier studies have suggested new treatment possibilities as a result of extending the traditionally prescribed dosing interval of oral antipsychotic drugs.^[@bibr8-2050313X17742836]^ Therefore, although conclusions cannot be made from the results of only one case in this study, the results suggest that adverse effects were decreased by the reduction in the paliperidone dose during the maintenance phase. There is a need for more clinical studies involving the screening of patient groups for whom paliperidone dose could be safely reduced.
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